| Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia M Konopleva, DA Pollyea, J Potluri, B Chyla, L Hogdal, T Busman, ... Cancer discovery 6 (10), 1106-1117, 2016 | 1016 | 2016 |
| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826, 2017 | 739 | 2017 |
| Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study AH Wei, SA Strickland Jr, JZ Hou, W Fiedler, TL Lin, RB Walter, A Enjeti, ... Journal of Clinical Oncology 37 (15), 1277-1284, 2019 | 637 | 2019 |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ... The lancet oncology 19 (1), 65-75, 2018 | 417 | 2018 |
| Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ... Journal of Clinical Oncology 36 (19), 1973-1980, 2018 | 341 | 2018 |
| Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM P Moreau, A Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ... Blood, The Journal of the American Society of Hematology 130 (22), 2392-2400, 2017 | 284 | 2017 |
| Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments SK Agarwal, CD DiNardo, J Potluri, M Dunbar, HM Kantarjian, ... Clinical Therapeutics 39 (2), 359-367, 2017 | 181 | 2017 |
| Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study SE Karol, TB Alexander, A Budhraja, SB Pounds, K Canavera, L Wang, ... The lancet oncology 21 (4), 551-560, 2020 | 117 | 2020 |
| Pharmacokinetics of venetoclax, a novel BCL‐2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non‐Hodgkin lymphoma AH Salem, SK Agarwal, M Dunbar, SLH Enschede, RA Humerickhouse, ... The Journal of Clinical Pharmacology 57 (4), 484-492, 2017 | 108 | 2017 |
| {ML-Doctor}: Holistic risk assessment of inference attacks against machine learning models Y Liu, R Wen, X He, A Salem, Z Zhang, M Backes, E De Cristofaro, M Fritz, ... 31st USENIX Security Symposium (USENIX Security 22), 4525-4542, 2022 | 100 | 2022 |
| Analyzing leakage of personally identifiable information in language models N Lukas, A Salem, R Sim, S Tople, L Wutschitz, S Zanella-Béguelin 2023 IEEE Symposium on Security and Privacy (SP), 346-363, 2023 | 87 | 2023 |
| Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma SK Agarwal, AH Salem, AV Danilov, B Hu, S Puvvada, M Gutierrez, ... British journal of clinical pharmacology 83 (4), 846-854, 2017 | 87 | 2017 |
| Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t (11; 14) multiple myeloma JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, ... American journal of hematology 96 (4), 418-427, 2021 | 84 | 2021 |
| Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor: results of a single‐and multiple‐dose study SK Agarwal, B Hu, D Chien, SL Wong, AH Salem The Journal of Clinical Pharmacology 56 (11), 1335-1343, 2016 | 84 | 2016 |
| Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis AK Jones, KJ Freise, SK Agarwal, RA Humerickhouse, SL Wong, ... The AAPS journal 18, 1192-1202, 2016 | 82 | 2016 |
| Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade FJ Kohlhapp, D Haribhai, R Mathew, R Duggan, PA Ellis, R Wang, ... Cancer Discovery 11 (1), 68-79, 2021 | 81 | 2021 |
| Statins enhance efficacy of venetoclax in blood cancers JS Lee, A Roberts, D Juarez, TTT Vo, S Bhatt, L Herzog, S Mallya, ... Science translational medicine 10 (445), eaaq1240, 2018 | 80 | 2018 |
| A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML) M Konopleva, DA Pollyea, J Potluri, BJ Chyla, T Busman, E McKeegan, ... Blood 124 (21), 118, 2014 | 79 | 2014 |
| Effect of low‐and high‐fat meals on the pharmacokinetics of venetoclax, a selective first‐in‐class BCL‐2 inhibitor AH Salem, SK Agarwal, M Dunbar, S Nuthalapati, D Chien, KJ Freise, ... The Journal of Clinical Pharmacology 56 (11), 1355-1361, 2016 | 78 | 2016 |
| Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study S de Vos, LJ Swinnen, D Wang, E Reid, N Fowler, J Cordero, M Dunbar, ... Annals of Oncology 29 (9), 1932-1938, 2018 | 72 | 2018 |
Ayman NoreddinAhram Canadian UniversityVerified email at acu.edu.eg
